SILVER SPRING, Md., June 26 (Reuters) - River Plate Biotechnology did not provide adequate evidence of safety and effectiveness for a proposed drug to treat dry eye, a U.S. advisory panel ruled on Friday.
The committee voted 6-1 against the drug, called Rejena. Alcon Inc (ACL.N) holds U.S. marketing rights for the product.
Tuesday, July 14, 2009
Drug news: Thumbs down to Rejena
US panel rejects River Plate, Alcon dry eye drug
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment